Nutrition, Metabolism & Cardiovascular Diseases
Volume 21, Issue 5 , Pages 339-346 , May 2011

The Direct Economic Cost of Pharmacologically-Treated Diabetes in Italy-2006. The ARNO Observatory

  • G. Marchesini

      Affiliations

    • Unit of Metabolic Diseases and Clinical Dietetics, “Alma Mater Studiorum” University, Bologna, Italy
    • Corresponding Author InformationCorresponding author. Unit of Metabolic Diseases and Clinical Dietetics, “Alma Mater Studiorum” University, S.Orsola-Malpighi Hospital, Via Massarenti, 9, I-40138 Bologna, Italy. Tel.: +39 51 6364889; fax: +39 51 6364502.
    • ,
  • G. Forlani

      Affiliations

    • Unit of Metabolic Diseases and Clinical Dietetics, “Alma Mater Studiorum” University, Bologna, Italy
    • ,
  • E. Rossi

      Affiliations

    • CINECA Interuniversity Consortium, Bologna, Italy
    • ,
  • A. Berti

      Affiliations

    • CINECA Interuniversity Consortium, Bologna, Italy
    • ,
  • M. De Rosa

      Affiliations

    • CINECA Interuniversity Consortium, Bologna, Italy
    • ,
  • on behalf of the ARNO Working Group

      Affiliations

    • ARNO working group: M. De Cal (Belluno), M. Cecchetto (Bassano), M. Cariolato (Ovest Vicentino), R. Gallo (Vicenza), D. Maccari (Pieve di Soligo), M. Ragazzi (Asolo), L. Cordella (Mirano), B. Pari (Chioggia), A. Pedrini (Alta Padovana), A.M. Grion (Padova), M.G. Zogno (Este), L. Monti (Rovigo), G. Rizzotti (Adria), L. Mezzalira (Verona), S. Brasola (Legnago), L. Castellani (Bussolengo), S. Chiorrini (Ancona), A.T. Calamia (Roma A), A. Blasi (Roma D), A. Orsini (Teramo), D. Garibaldi (Lucca), F. Lena (Livorno), P. Batacchi (Firenze), M. Rais (Viareggio), A. Coccini (Genova), R. Carniglia De Carli (Chiavari), A. Sarteschi (La Spezia), A. Tamburrino (Caserta2), G. La Bella (Napoli1), E. Nava (Napoli4).

Received 15 February 2009 ,Revised 23 September 2009 ,Accepted 9 October 2009.

References 

  1. American Diabetes Association . Economic costs of diabetes in the U.S. in 2007. Diabetes Care. 2008;31:596–615
  2. Gulliford MC, Latinovic R, Charlton J. Diabetes diagnosis, resource utilization, and health outcomes. The American Journal of Managed Care. 2008;14:32–38
  3. Bruno G, Karaghiosoff L, Merletti F, Costa G, De Maria M, Panero F, et al. The impact of diabetes on prescription drug costs: the population-based Turin study. Diabetologia. 2008;51:795–801
  4. Lucioni C, Garancini MP, Massi-Benedetti M, Mazzi S, Serra G. CODE-2 Italian Advisory Board. The costs of type 2 diabetes mellitus in Italy: a CODE-2 sub-study. Treatments in Endocrinology. 2003;2:121–133
  5. Sullivan PW, Ghushchyan V, Wyatt HR, Hill JO. The medical cost of cardiometabolic risk factor clusters in the United States. Obesity. 2007;15:3150–3158
  6. Bottomley JM, Raymond FD. Pharmaco-economic issues for diabetes therapy. Best Practice & Research. 2007;21:657–685
  7. Henriksson F, Agardh CD, Berne C, Bolinder J, Lonnqvist F, Stenstrom P, et al. Direct medical costs for patients with type 2 diabetes in Sweden. Journal of Internal Medicine. 2000;248:387–396
  8. Jonsson B, CODE-2 Advisory Board . Revealing the cost of Type II diabetes in Europe. Diabetologia. 2002;45:S5–12
  9. Koster I, von Ferber L, Ihle P, Schubert I, Hauner H. The cost burden of diabetes mellitus: the evidence from Germany–the CoDiM study. Diabetologia. 2006;49:1498–1504
  10. Liebl A. Costs involved in the early and late phases of diabetes mellitus, International Journal of Dermatology. 2007;48:708–714
  11. Schwarz PE, Lindstrom J, Kissimova-Scarbeck K, Szybinski Z, Barengo NC, Peltonen M, et al. The European perspective of type 2 diabetes prevention: diabetes in Europe - prevention using lifestyle, physical activity and nutritional intervention (DE-PLAN) project. Experimental and Clinical Endocrinology and Diabetes. 2008;116:167–172
  12. Soljak MA, Majeed A, Eliahoo J, Dornhorst A. Ethnic inequalities in the treatment and outcome of diabetes in three English Primary Care Trusts. International Journal for Equity in Health. 2007;6:8
  13. Stock SA, Redaelli M, Wendland G, Civello D, Lauterbach KW. Diabetes–prevalence and cost of illness in Germany: a study evaluating data from the statutory health insurance in Germany. Diabetic Medicine. 2006;23:299–305
  14. Wallemacq C, Van Gaal LF, Scheen AJ. The cost of type 2 diabetes: summary of the cost of diabetes in Europe-Type II study (CODE-2) and analysis of the situation in Belgium, Revue Medicale de Liege. 2005;60:278–284
  15. Dawson KG, Gomes D, Gerstein H, Blanchard JF, Kahler KH. The economic cost of diabetes in Canada, 1998. Diabetes Care. 2002;25:1303–1307
  16. Orszag PR, Ellis P. Addressing rising health care costs–a view from the congressional budget office. The New England Journal of Medicine. 2007;357:1885–1887
  17. Weinstock RS, Hawley G, Repke D, Feuerstein BL, Sawin CT, Pogach LM. Pharmacy costs and glycemic control in the department of veterans affairs. Diabetes Care. 2004;27(Suppl. 2):B74–81
  18. Davis WA, Knuiman MW, Hendrie D, Davis TM. The obesity-driven rising costs of type 2 diabetes in Australia: projections from the Fremantle Diabetes Study. Internal Medicine Journal. 2006;36:155–161
  19. Kapur A. Economic analysis of diabetes care. The Indian Journal of Medical Research. 2007;125:473–482
  20. Oishi M, Yokoyama H, Abe N, Iwasaki K, Okuguchi F, Kawai K, et al. Time and cost involved in the care of newly registered patients with diabetes mellitus and other lifestyle diseases at diabetes clinics in Japan (JDDM 4). Diabetic Medicine. 2007;24:1149–1155
  21. Cowie CC, Rust KF, Byrd-Holt DD, Eberhardt MS, Flegal KM, Engelgau MM, et al. Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population: national health and nutrition examination survey 1999–2002. Diabetes Care. 2006;29:1263–1268
  22. Narayan KM, Boyle JP, Geiss LS, Saaddine JB, Thompson TJ. Impact of recent increase in incidence on future diabetes burden: U.S., 2005–2050. Diabetes Care. 2006;29:2114–2116
  23. Brown DA, Unrein C. A review of cardiovascular comorbidities in diabetes. American Journal of Managed Care. 2007;13:3–10
  24. Adeyi O, Smith O, Robles S. Public policy and the challenge of chronic noncommunicable diseases. Washington, D.C.: The World Bank; 2007;
  25. Goetzel RZ, Hawkins K, Ozminkowski RJ, Wang S. The health and productivity cost burden of the “top 10” physical and mental health conditions affecting six large U.S. employers in 1999. Journal of Occupational and Environmental Medicine. 2003;45:5–14
  26. The Economist Intelligence Unit. The silent epidemics. An economic study of diabetes in developed and developing countries. London; 2007.
  27. Goetzel RZ, Ozminkowski RJ, Villagra VG, Duffy J. Return on investment in disease management: a review. Health Care Financial Review. 2005;26:1–19

PII: S0939-4753(09)00255-5

doi: 10.1016/j.numecd.2009.10.009

Nutrition, Metabolism & Cardiovascular Diseases
Volume 21, Issue 5 , Pages 339-346 , May 2011

Article Tools

* Image Usage & Resolution